← Back to All Filings

Guardant Health CLO Sells $866K in GH Stock

Low SignificanceNovember 10, 2025 at 7:32:12 PM EST

Guardant Health, Inc.

$GH4CIK: 0001576280

Subscribe to track GH

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

Guardant Health CLO Sells $866K in GH Stock

Company: Guardant Health, Inc. (GH) Form: 4 | Filed: 2025-11-10 Significance: Low

Insider: Saia John G. Title: Chief Legal Officer | Relationship: Officer

Transaction: • Type: Sale • Shares: 8,996 • Price: $96.25 • Value: $865,865 • Owned After: 43,172

Key Insight: The Chief Legal Officer sold shares valued at approximately $866k. The transaction is considered low significance as it represents less than 0.01% of the company's market capitalization.

Market Context: This sale is a routine transaction for an executive at a multi-billion dollar company and is unlikely to impact the market. The sale constituted about 17% of the insider's direct holdings.

View Full Filing

This is PUBLIC SEC data for educational purposes. Not investment advice.

Comprehensive Analysis

SEC Filing Analysis: Guardant Health, Inc. (GH)

Executive Summary

  • Trading Significance: Low
  • Key Takeaway: The Chief Legal Officer, John G. Saia, executed a routine sale of common stock valued at approximately $866k.
  • Market Impact: The transaction is immaterial relative to the company's market capitalization and is not expected to influence the stock price.

Company Information

FieldValue
CompanyGuardant Health, Inc.
Ticker SymbolGH
CIK0001576280
IndustrySERVICES-MEDICAL LABORATORIES

Insider Information

FieldValue
NameSaia John G.
CIK0001737840
Title/PositionChief Legal Officer
RelationshipOfficer

Transaction Details

FieldValue
Form Type4
Transaction Date2025-11-07
Transaction CodeS (Sale)
Security TypeCommon Stock
Shares Involved8,996
Price Per Share$96.25
Total Value$865,865
Shares Owned After43,172
Ownership TypeDirect

Financial Impact Assessment

Transaction Materiality

MetricValue
Transaction Value$865,865
% of Market Cap0.0071%
Shares Transacted8,996
% of Shares Outstanding0.0072%
Post-Transaction Ownership43,172 shares (0.035% of outstanding)
Materiality AssessmentLow

Impact Evaluation

  • Market Cap Context: For a company with a market capitalization of $12.19 billion, this transaction of under $1 million is financially insignificant and considered routine portfolio management.
  • Ownership Concentration: The insider's post-transaction ownership of 43,172 shares represents a very small fraction (0.035%) of the total shares outstanding, indicating low ownership concentration.
  • Transaction Significance: The sale represents approximately 17.2% of the insider's direct holdings. While a notable portion of their personal stake, its size relative to the company's total float and market cap renders it a low-significance event from a market perspective.

Market Impact Analysis

Stock Impact Prediction

  • Direction: Neutral
  • Reasoning: The transaction value is less than 0.01% of the company's market capitalization, making it too small to have any meaningful impact on stock price or trading dynamics.

Volume & Sentiment

  • Expected Volume Impact: Negligible. The transaction size is a minor fraction of typical daily trading volume for a stock of this size.
  • Sentiment Indicator: Neutral. The market is unlikely to interpret this small, routine sale by an officer as a significant signal.

Additional Context

Transaction Notes

  • Timing: The transaction was reported promptly within the required timeframe.
  • Special Circumstances: The filing does not indicate that this sale was made pursuant to a pre-arranged 10b5-1 trading plan.
Topics:#SECFiling#InsiderTrading#GH#GuardantHealth#Form4#InsiderSell#StockMarket#MarketAnalysis

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.